Priliximab

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease and multiple sclerosis but has not yet received FDA licencing. The patent belongs to the biotechnology company Centocor.